Succeeder(SH:688338) Sou Hu Cai Jing·2025-07-08 12:13Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Saikohide, a company in the medical device industry, which is currently facing a decline in revenue and profit [1][2] - As of July 8, Saikohide's stock closed at 25.31 yuan, with a rolling PE ratio of 25.42, marking a new low in 64 days, and a total market capitalization of 2.686 billion yuan [1] - The average PE ratio for the medical device industry is 51.58, with a median of 37.46, positioning Saikohide at 55th place among its peers [1][2] Group 2 - Saikohide's main business focuses on the development, production, and sales of diagnostic instruments, reagents, and consumables in the field of thrombosis and hemostasis [1] - The latest quarterly report for Q1 2025 shows that the company achieved revenue of 68.6393 million yuan, a year-on-year decrease of 9.47%, and a net profit of 23.1329 million yuan, down 23.98%, with a gross profit margin of 62.49% [1] - As of March 31, 2025, Saikohide had 6,725 shareholders, an increase of 1,118 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1]